News

Hemogenyx Pharmaceuticals plc is an LSE Main Market listed clinical-stage biotechnology company (LSE: HEMO) focused on developing innovative therapies for blood cancers, autoimmune disorders, and viral infections. The company is headquartered in London and conducts much of its research and development through its U.S. subsidiaries in New York.

Hemogenyx is developing a portfolio of cell therapies, immunotherapies, and transplantation technologies designed to address serious diseases where current treatment options are limited. Its strategy centres on using proprietary technology platforms to create novel therapies with potentially significant clinical benefits.

Publication of Annual Report

The Perivan shareholder communications team was delighted to work with Westend Corporate on the publication and production of the annual report which was posted to shareholders on 3 June 2026.

Perivan is the UK’s leading designer and producer of annual reports. For further information, click here.